Asenapine

Active ingredient description

The mechanism of action of asenapine is not fully understood. However, based on its receptor pharmacology, it is proposed that the efficacy of asenapine is mediated through a combination of antagonist activity at D2 and 5-HT2A receptors. Actions at other receptors e.g. 5-HT1A, 5-HT1B, 5-HT2C, 5-HT6, 5-HT7, D3, and a2-adrenergic receptors, may also contribute to the clinical effects of asenapine.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
N05AH05
Asenapine
N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AH Diazepines, oxazepines and thiazepines
Discover more medicines within N05AH05

Medicines

$substanceName is the active ingredient of these drugs:

Drug
Countries
SAPHRIS

Australia Canada New Zealand United States

SECUADO

United States

SYCREST

Austria Cyprus Estonia Finland Ireland

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
SAPHRIS Tablet
Structured Product Labeling (SPL/PLR)
US
SYCREST Sublingual tablet
Summary of Product Characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Molecular mass: 285.77 g/mol

External identifiers

CAS Substance: 65576-45-6
DrugBank Drug: DB06216
KEGG Drug: D02995
RxNorm Ingredient: 784649
SNOMED-CT Concept: 443375003
Asenapine (substance)
UNII Identifier: JKZ19V908O
ASENAPINE
 
Next: Usage >